Previous 10 | Next 10 |
The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Investor Presentation
ALX Oncology (NASDAQ:ALXO): Q3 GAAP EPS of -$0.61 misses by $0.14. Press Release. For further details see: ALX Oncology EPS misses by $0.14
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quart...
Gainers: Dover Motorsports (NYSE:DVD) +57%. TDH Holdings (NASDAQ:PETZ) +40%. New Relic (NYSE:NEWR) +35%. Roblox (NYSE:RBLX) +32%. Guaranty Federal Bancshares (NASDAQ:GFED) +31%. Bit Brother (NASDAQ:BTB) +29%. Altimeter Growth (NASDAQ:AGC) +26%. Altimeter Growth (NASDAQ:AGCUU) +26%. Katapult (...
Shares of ALX Oncology (NASDAQ:ALXO) are down 5% premarket after the company released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. Updated results were in two cohorts: gastric/gastroesophageal junction cancer patients receiving evorpacept plus Her...
-- ORR of 72.2%, mDOR of 14.8 months, 12-month OS rate of 79%, and mOS of 17.1 months in Patients with > 2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- -- 12-month OS rate of 87.5% and mOS not reached in Patients with 1L Head and Neck Cancer -- ...
ALX Oncology (ALXO -23.3%) shares have lost more than a fifth to reach a 12-month low after the company released preliminary data for its lead asset evorpacept from a Phase 1/2 trial in combination with chemotherapy azacitidine in myelodysplastic syndromes (“MDS”). As of mi...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the Company will be presenting early ...
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in...
Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates Expands ALX Oncology’s pipeline of drug candidates based on expertise in protein engineeri...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...